


AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

In the Claims:

Claim 1 (currently amended): A compound of Formula (I):



wherein:

each R is independently alkyl or cycloalkyl;

R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino,

monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino,

guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

~~$\text{Ar}^1, \text{Ar}^2, \text{Ar}^3$, and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and~~

L is:

- (i) alkylene or cycloalkylene;
- (ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR^4 (wherein R^4 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or $\text{-(CHR}^5\text{)}_{n1}\text{-CO-(NH-Ar}^3\text{-CO)}_m\text{-NH-Ar}^4\text{-CO-NHR}^3$ where $n1$ is 1 to 3, R^5 is hydrogen or alkyl, substituted alkyl, and Ar^3 , Ar^4 , and R^3 are as defined above), -CONHNHR^6 [wherein R^6 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR^7 , -COOR^8 (wherein R^7 and R^8 are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR^9 (wherein R^9 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or
- (iii) $\text{-(alkylene)}_x\text{-Z-(alkylene)}_y\text{-(Z}^a\text{)}_z$ wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O- , -S- , -NR^{10} [wherein R^{10} is hydrogen, alkyl,


substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, $-\text{CONHR}^4$, $-\text{COR}^7$, $-\text{COOR}^8$ (where R^4 , R^7 and R^8 are as defined above), $-\text{SO}_2\text{R}^{11}$ (where R^{11} is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or $-(\text{CHR}^5)_{n2}-\text{NH}-(\text{CO}-\text{Ar}^3-\text{NH})_m-\text{CO}-\text{Ar}^4-\text{NHR}^2$ where $n2$ is 2 to 4, R^5 is hydrogen, alkyl, or substituted alkyl, and Ar^3 , m , Ar^4 , and R^2 are as defined above], $-\text{CO}-\text{NH}-$, or $-\text{NH}-\text{CO}-$, provided that

when Z and/or Z^a is $-\text{NR}^{10}$ - then it is separated from another nitrogen atom by at least two carbon atoms;

or a pharmaceutically acceptable salt thereof.

Claim 2 (canceled)

Claim 3 (currently amended): ~~The compound of Claim 2 wherein Ar^1 , Ar^2 , Ar^3 and Ar^4 are independently a 1-methylpyrrole that is linked to the carbonyl group at the 2-position and the amino group at the 4-position of the pyrrole ring.~~ A compound of the formula:



R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-\text{COR}^3$ wherein R^3 is selected from the group consisting of alkyl, amino,

monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents

selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is:

- (i) alkylene or cycloalkylene;
- (ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR⁴ (wherein R⁴ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or -(CHR⁵)_{n1}-CO-(NH-Ar³-CO)_m-NH-Ar⁴-CO-NHR³ where n1 is 1 to 3, R⁵ is hydrogen or alkyl, substituted alkyl, and Ar³, m, Ar⁴, and R³ are as defined above), -CONHNHR⁶ [wherein R⁶ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR⁷, -COOR⁸ (wherein R⁷ and R⁸ are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR⁹ (wherein R⁹ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or
- (iii) -(alkylene)_x-Z-(alkylene)_y-(Z^a)_z- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR¹⁰- [wherein R¹⁰ is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, -CONHR⁴,

-COR⁷, -COOR⁸ (where R⁴, R⁷ and R⁸ are as defined above), -SO₂R¹¹ (where R¹¹ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -(CHR⁵)_{n2}-NH-(CO-Ar³-NH)_m-CO-Ar⁴-NHR² where n2 is 2 to 4, R⁵ is hydrogen, alkyl, or substituted alkyl, and Ar³, m, Ar⁴, and R² are as defined above], -CO-NH-, or -NH-CO-, provided that
when Z and/or Z^a is -NR¹⁰- then it is separated from another nitrogen atom by at least two carbon atoms;
or a pharmaceutically acceptable salt thereof.


Claim 4 (original): The compound of Claim 1 wherein n and m are 0 or 1.

Claim 5 (canceled):

Claim 6 (currently amended): The compound of Claim 1 wherein R¹ and R² are independently -COR³.

Claim 7 (currently amended): The compound of Claim 6 wherein R¹ and R² are independently aminomethylcarbonyl, 1-amino-4-guanidinobutylcarbonyl, 1,4-diaminobutylcarbonyl, 1,5-diaminopentyl-carbonyl, 1-amino-5-(3,4difluorophenylureido)-pentylcarbonyl, 1-(3,4-difluoro-phenylureido)-4-guanidinobutylcarbonyl, 1-[4-(N,N-(2-chloroethyl)-aminophenylbutanoyl)]amino-4-guanidinobutylcarbonyl, or 1-amino-5-[4-(N,N-(2-chloroethyl)-aminophenyl-butanoyl)]aminopentylcarbonyl ~~or pyrene-1-ylmethoxy~~.

Claim 8 (currently amended): ~~The compound of Claim 1 wherein~~ A compound of the Formula (I):



wherein:

each R is independently alkyl or cycloalkyl;

R¹ and R² are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) -COR³ wherein R³ is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;


n and m are independently an integer from 0 to 4; and

L is alkylene;

or a pharmaceutically acceptable salt thereof.

Claim 9 (original): The compound of Claim 8 wherein L is 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,6-hexylene, 1,8-octylene, 1,12-dodecylene, 1-methylethylene, or 1,2-hexadecylene.

Claim 10 (currently amended): ~~The compound of Claim 1 wherein~~ A compound of the Formula (I):



wherein:

each R is independently alkyl or cycloalkyl;

R¹ and R² are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) -COR³ wherein R³ is selected from the group consisting of alkyl, amino,

monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents

selected from the group consisting of amino, monosubstituted amino, disubstituted amino,

guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl,

substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl,

substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted

heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl,

substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted

alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;


n and m are independently an integer from 0 to 4; and

L is substituted alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR⁴ (wherein R⁴ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or -(CHR⁵)_{n1}-CO-(NH-Ar³-CO)_m-NH-Ar⁴-CO-NHR³ where n1 is 1 to 3, R⁵ is hydrogen or alkyl, substituted alkyl, and Ar³, m, Ar⁴, and R³ are as defined above), -CONHNHR⁶ [wherein R⁶ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR⁷, -COOR⁸ (wherein R⁷ and R⁸ are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR⁹ (wherein R⁹ is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino;
or a pharmaceutically acceptable salt thereof.

Claim 11 (original): The compound of Claim 10 wherein L is meso-1,2-diphenylethylene, 1-(p-nitrophenylaminocarbonyl)-1,5-pentylene, 1-(naph-2-ylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,5-pentylene, 1-(5-trifluoro-pyrimidin-2-ylhydrazidocarbonyl)-1,5-pentylene, 1-(2-pyrene-lylethylamino-carbonyl)-1,5-pentylene, 1-[2-(6-nitrobenzimidazol-1-ylethylaminocarbonyl)-1,5-pentylene, 1-[2-(indol-3-yl)-ethylaminocarbonyl]-1,5-pentylene, 1-[2-(5-fluoroindol-3-yl)ethylaminocarbonyl]-1,5-pentylene, 1-[2-(4-nitrophenyl)ethylaminocarbonyl]-1,5-pentylene, 1-(benzyloxycarbonyl-hydrazidocarbonyl)-1,2-ethylene, 1-(naph-1-ylaminocarbonyl)-1,5-pentylene, 1-(4-pyrene-1-ylbutylaminocarbonyl)-1,5-pentylene, 1-(2-(2-trifluoromethylquinolin-4-yl)thio-ethylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,4-butylene, 1-(4-pyrene-1-ylmethylaminocarbonyl)-1,5-

pentylene, 1-(2-hydroxyethylaminocarbonyl)-1,5-pentylene, 1-(2-aminoethylaminocarbonyl)-1,5-pentylene, 1-(3-dimethylaminopropyl-aminocarbonyl)-1,5-pentylene, 1-(bis-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 1-(N-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 2-(aminomethylcarbonyl-amino)-1,3-propylene, or 2-(3-hydroxypyrrolidin-5-ylcarbonyl-amino)-1,3-propylene.

Claim 12 (currently amended): ~~The compound of Claim 1 wherein~~ A compound of the Formula (I):



wherein:

each R is independently alkyl or cycloalkyl;

R¹ and R² are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) -COR³ wherein R³ is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl,

substituted heteroaryl, carboxy, alkoxy carbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is -(alkylene)_x-Z-(alkylene)_y-(Z^a)_z- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR¹⁰- [wherein R¹⁰ is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, -CONHR⁴, -COR⁷, -COOR⁸ (where R⁴, R⁷ and R⁸ are as defined above), -SO₂R¹¹ (where R¹¹ is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -(CHR⁵)_{n2}-NH-(CO-Ar³-NH)_m-CO-Ar⁴-NHR² where n2 is 2 to 4, R⁵ is hydrogen, alkyl, or substituted alkyl, and Ar³, m, Ar⁴, and R² are as defined above], -CO-NH-, or -NH-CO-,

provided that when Z and/or Z^a is -NR¹⁰- then it is separated from another nitrogen atom by at least two carbon atoms;


or a pharmaceutically acceptable salt thereof.

Claim 13 (original): The compound of Claim 12 wherein L is m-xylene, p-xylene, 2,7-fluorendiyl, *bis*-(3-N-benzoyloxycarbonylamino)propylene [-(CH₂)₃-N(BzOCO)- (CH₂)₃-], *bis*-(2-naphth-2-ylsulfonylamino)ethylene [-(CH₂)₂-N(-SO₂naphth-2-yl)-(CH₂)₂-], *bis*-(2-N-3,5-dinitrophenylcarbonylamino)ethylene [-(CH₂)₂-N(-CO-3,5-dinitrophenyl)-(CH₂)₂-], 1,3-cyclohexyl-bis-methylene [-(CH₂)-(1,3-C₆H₁₀)-(CH₂)₂-], 1,4-cyclohexyl-bis-methylene [-(CH₂)-(1,4-C₆H₁₀)-(CH₂)₂-], 4,4'-methylene-bis-1,4-cyclohexylene [-(1,4-C₆H₁₀)-(CH₂)-(1,4-C₆H₁₀)-], 1,2-cyclohexylene (1,2-C₆H₁₀-), *bis*-(2-adamantyl-ylcarbonylamino)ethylene, *bis*-(3-N-methylamino)propylene [-(CH₂)₃-N(-CH₃)-(CH₂)₃-], *bis*-(3-amino)propylene [-(CH₂)₃-NH-(CH₂)₃-], 1,4-piperazino- *bis*-propylene [-(CH₂)₃-(1,4-piperazino)-(CH₂)₃-], *bis*-(2-(2-aminoethyl)amino)ethylene [-(CH₂)₂-N(-(CH₂)₂NH₂)-(CH₂)₂-], and *bis*-(2-amino)ethylene [-(CH₂)₂-NH-(CH₂)₂-] .

Claim 14 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~Claims 1-13~~ any one of Claims 1, 3-4 and 6-13 and a pharmaceutically suitable carrier.

Claim 15-19 (canceled)

Claim 20 (previously presented): A compound of claim 1 which compound is represented by formula (VII)




wherein


L is selected from the group consisting of alkylene and cycloalkylene;

A is an amino acid side chain; and


R²³ is selected from the group consisting of guanidino, amino, and ornithylamino.

Claim 21 (original): A compound of claim 20 selected from the group consisting of







177




173




169



171



170



172

and pharmaceutically acceptable salts thereof.

Claim 22 (canceled):